Patients receiving any medications or substances that are strong inhibitors or inducers of CYPA enzymes are ineligible; these include St. Johns wort or hyperforin (potent CYPA enzyme inducer) and grapefruit juice (potent cytochrome P CYPA enzyme inhibitor); such substances can significantly increase or decrease the serum level of cobimetinib; as part of the enrollment/informed consent procedures, the patient will be counseled on the risk of interactions with other agents, and what to do if new medications need to be prescribed or if the patient is considering a new over-the-counter medicine or herbal product
Participants receiving any medications or substances that are strong inhibitors or inducers of CYPA or moderate inhibitors of CYPA are ineligible; the study team should check a frequently-updated medical reference for a list of drugs to avoid or minimize use of; as part of the enrollment/informed consent procedures, the patient will be counseled on the risk of interactions with other agents, and what to do if new medications need to be prescribed or if the patient is considering a new over-the-counter medicine or herbal product; dihydropyridine calcium-channel blockers are permitted for management of hypertension; patient drug information handout and wallet card should be provided to patients
Participants receiving any medications or substances that are strong inhibitors or inducers of CYPA/ are ineligible; the required washout period prior to starting treatment is  weeks for CYPA inhibitors,  weeks for CYPA inducers, and  weeks for enzalutamide; dihydropyridine calcium-channel blockers are permitted for management of hypertension
The following medications or non-drug therapies are also prohibited while on treatment in this study:\r\n* Other anti-cancer therapies\r\n* Other investigational drugs\r\n* Patients taking any medications or substances that are strong inhibitors or inducers of CYPA or CYPC are ineligible
Patients receiving any medications or substances that are potent inhibitors or inducers of
Participants receiving any medications or substances that are inhibitors of cytochrome P, family , subfamily A, polypeptide  (CYPA) are ineligible; as part of the enrollment/informed consent procedures, the participant will be counseled on the risk of interactions with other agents, and what to do if new medications need to be prescribed or if the patient is considering a new over-the-counter medicine or herbal product
Patients receiving any medications or substances that are strong inhibitors of CYP A isoenzyme are ineligible; patients must be off the strong inhibitor for at least  week prior to being deemed eligible
Receiving any medications or substances that are inducers of CYPA; use of inducers are prohibited =<  days prior to randomization
Participants receiving any medications or substances that are moderate and/or potent enzyme inducers or inhibitors which may have an effect on the metabolism of bavituximab; as part of the enrollment/informed consent procedures, the patient will be counseled on the risk of interactions with other agents, and what to do if new medications need to be prescribed or if the patient is considering a new over-the-counter medicine or herbal product
Participants receiving any medications or substances that are moderate or strong inhibitors or inducers of CYPA isoenzymes are ineligible; lists including medications and substances known or with the potential to interact with the CYPA isoenzymes
The use of CYPC and CYPA inhibitors/inducers while not prohibited in this study, is discouraged whenever feasible; concurrent use of strong CYPC and CYPA inhibitors/inducers should be documented and the principal investigator (PI) of the study shall be notified prior to dosing; as part of the enrollment/informed consent procedures, the patients will be counseled on the risk of interactions with other agents, and what to do if new medications need to be prescribed or if the patient is considering a new over-the-counter medicine or herbal product
Participants receiving any medications or substances that are strong inhibitors or inducers of CYPA are ineligible; as part of the enrollment/informed consent procedures, the patient will be counseled on the risk of interactions with other agents, and what to do if new medications need to be prescribed or if the patient is considering a new over-the-counter medicine or herbal product
Participants receiving any medications or substances that are strong or moderate inhibitors or inducers of CYPA are ineligible; as part of the enrollment/informed consent procedures, the patient will be counseled on the risk of interactions with other agents, and what to do if new medications need to be prescribed or if the patient is considering a new over-the-counter medicine or herbal product
Patients who require concurrent treatment with any medications or substances that are potent inhibitors or inducers of cytochrome P A (CYPA) are ineligible
Receiving any medications or substances that are potent inhibitors or inducers of CYPA isoenzymes within  days prior to registration
Concomitant administration with strong inhibitors or inducers of CYPA should be avoided; medications that enhance glucuronidation (i.e. phenytoin, phenobarbital, carbamazepine, rifampin, etc.) should be avoided; it is important to regularly consult a frequently-updated medical reference for a list of drugs to avoid or minimize use of; as part of the enrollment/informed consent procedures, the patient will be counseled on the risk of interactions with other agents, and what to do if new medications need to be prescribed or if the patient is considering a new over-the-counter medicine or herbal product
Concomitant administration with strong inhibitors or inducers of cytochrome P, family , subfamily A, polypeptide  (CYPA) should be avoided; it is important to regularly consult a frequently-updated medical reference for a list of drugs to avoid or minimize use of; patients receiving any medications or substances that are inhibitors or inducers of cytochrome P A (CYPA enzyme) are ineligible; as part of the enrollment/informed consent procedures, the patient will be counseled on the risk of interactions with other agents, and what to do if new medications need to be prescribed or if the patient is considering a new over-the-counter medicine or herbal product
Receiving any medications or substances which in the opinion of the investigators would interfere with treatment; examples could include strong inhibitors of CYPA at oncologist discretion
Patients receiving any medications or substances that are strong inhibitors or inducers of CYPA are ineligible. As part of the enrollment/informed consent procedures, the patient will be counseled on the risk of interactions with other agents, and what to do if new medications need to be prescribed or if the patient is considering a new over-the-counter medicine or herbal product. Strong inhibitors and inducers of CYPA are prohibited within  weeks before the start of and during treatment. Strong inhibitors and inducers of CYPC should be used with caution; the PI of the study is to be consulted regarding their use
Participants receiving any medications or substances that are strong inhibitors or inducers of CYPA are ineligible; as part of the enrollment/informed consent procedures, the patient will be counseled on the risk of interactions with other agents, and what to do if new medications need to be prescribed or if the patient is considering a new over-the-counter medicine or herbal product
Patients receiving any medications or substances that are strong inhibitors or inducers of CYPA complex. Lists including medications and substances known or with the potential to interact with the CYPA isoenzymes
Patients receiving any medications or substances that are moderate to strong inhibitors CYPA are ineligible
Patients receiving any medications or substances that are inhibitors or inducers of CYPA are ineligible; these include herbal preparation containing CYPA inducers (e.g., St. Johns wort), grapefruit and grapefruit juice (CYPA inhibitor) within  weeks before the start of study treatment; as part of the enrollment/informed consent procedures, the patient will be counseled on the risk of interactions with other agents and what to do if new medications need to be prescribed or if the patient is considering a new over-the-counter medicine or herbal product
No studies have been performed to assess potential metabolic and transport interactions of TRC; as part of the enrollment/informed consent procedures, the patient will be counseled on the risk of interactions with other agents, and what to do if new medications need to be prescribed or if the patient is considering a new over-the-counter medicine or herbal product; the case report form must capture the concurrent use of all other drugs, over-the-counter medications, or alternative therapies
Caution should be taken with the use of hydroxychloroquine and any drugs known to interact with it; as part of the enrollment/informed consent procedures, the patient will be counseled on the risk of interactions with other agents, and what to do if new medications need to be prescribed or if the patient is considering a new over-the-counter medicine or herbal product
Patients receiving any medications or substances that are strong inhibitors or inducers of CYPA are ineligible
Patients receiving any medications or substances that are potent inhibitors or inducers of CYPA or CYPD are ineligible
Patients receiving any medications or substances that are strong inhibitors or inducers of CYPA and/or CYPA are ineligible
mCRPC EXPANSION COHORT: Patients receiving any medications or substances that are strong and moderate inhibitors or inducers of CYPA are ineligible
Patients receiving any medications or substances that are moderate or strong inhibitors or inducers of cytochrome P, family , subfamily A, polypeptide  (CYPA) are ineligible; as part of the enrollment/informed consent procedures, the patient will be counseled on the risk of interactions with other agents, and what to do if new medications need to be prescribed or if the patient is considering a new over-the-counter medicine or herbal product
Patients receiving any medications or substances that are inhibitors or inducers of nonsteroidal anti-inflammatory drugs (NSAIDS), probenecid, salicylates, sulfonamides are ineligible; concomitant drugs that are sensitive CYP substrates or strong and moderate CYP inducers and inhibitors should be avoided; as part of the enrollment/informed consent procedures, the patient will be counseled on the risk of interactions with other agents, and what to do if new medications need to be prescribed or if the patient is considering a new over-the-counter medicine or herbal product
Subjects requiring any medications or substances that are strong inhibitors or inducers of CYPA during the course of the study are ineligible
PHASE I STUDY ELIGIBILITY CRITERIA:\r\nPatients receiving any medications or substances that are strong inhibitors or inducers of CYPA are ineligible; dihydropyridine calcium-channel blockers are permitted for management of hypertension
PHASE II STUDY COHORT  TRIPLE NEGATIVE BREAST CANCER ELIGIBILITY CRITERIA (MEDI+O ONLY):\r\nPatients receiving any medications or substances that are strong inhibitors or inducers of CYPA are ineligible; dihydropyridine calcium-channel blockers are permitted for management of hypertension
PHASE II COLORECTAL CANCER COHORT  (MEDI+C ONLY):\r\nPatients receiving any medications or substances that are strong inhibitors or inducers of CYPA are ineligible; dihydropyridine calcium-channel blockers are permitted for management of hypertension
Receiving any medications or substances that are inducers of CYPA; use of inducers are prohibited =<  days prior to registration
Participants receiving any medications or substances that are strong inhibitors or inducers of CYPA or moderate inhibitors of CYPA are ineligible; the study team should check a frequently-updated medical reference for a list of drugs to avoid or minimize use of; as part of the enrollment/informed consent procedures, the patient will be counseled on the risk of interactions with other agents, and what to do if new medications need to be prescribed or if the patient is considering a new over-the-counter medicine or herbal product
Participants receiving any medications or substances that are potent inhibitors of CYPA, including grapefruit juice are ineligible; participants receiving fluconazole are also ineligible
Patients receiving any medications or substances that are substrates, inducers, or inhibitors of cytochrome P C (CYPC) enzyme
DOSE ESCALATION COHORT: Current use or anticipated need for treatment with any medications or substances that are inhibitors or inducers of CYPA
DOSE EXPANSION COHORT: Current use or anticipated need for treatment with any medications or substances that are inhibitors or inducers of CYPA
Patients who need chronic use of medications or substances that are strong inhibitors or inducers of CYPA are ineligible
Patients receiving any medications or substances to treat active infection
Concurrent use of medications or substances that are strong inhibitors of CYA are ineligible
Receiving any medications or substances that are inducers of cytochrome CYP C; use of the following inducers is prohibited =<  days prior to registration\r\n* Inducer of CYPC: rifampin
Receiving any medications or substances that are inducers of CYP C; use of the following inducers is prohibited =<  days prior to registration\r\n* Inducers of CYPC: rifampin, secobarbital
PHASE II: Patients must NOT be taking current medications or substances that are inhibitors or inducers of CYPA
Patients who require prohibited medications with potential for serious interactions with protocol therapy, and who cannot have therapeutic substitution are excluded; patients receiving any medications or substances that are inhibitors or inducers of cytochrome P (CYP) enzyme(s) are ineligible
Receiving any medications or substances that are inducers of CYPA; use of inducers are prohibited =<  days prior to registration
Patients receiving any medications or substances that are strong inhibitors or inducers of CYPA
Patients receiving any medications or substances that are inhibitors or inducers of CYP enzyme(s) are ineligible
PHASE II: Participants receiving any medications or substances that are strong inhibitors of CYPA are ineligible
Receiving any medications or substances that are inducers of CYPA\r\n* Use of inducers is prohibited =<  days prior to registration
Patients receiving any medications or substances that are strong inhibitors or inducers of cytochrome P A (CYPA) complex are ineligible
Patients who require taking drugs that are strong inhibitors/inducers of cytochrome P, family , subfamily A, polypeptide  (CYPA) and cannot be switched to an alternative medication; as part of the enrollment/informed consent procedures, the patient will be counseled on the risk of interactions with other agents, and what to do if new medications need to be prescribed or if the patient is considering a new over-the-counter medicine or herbal product
Participants receiving any medications or substances that are strong inhibitors or inducers of CYPA isoenzymes are ineligible
Patients who require treatment with strong CYPA inhibitors at the time of study enrollment; for patients who can safely discontinue prior strong CYPA inhibitor, a wash-out period of  effective half-lives is required prior to st dose of ibrutinib; as part of the enrollment/informed consent procedures, the patient will be counseled on the risk of interactions with other agents, and what to do if new medications need to be prescribed or if the patient is considering a new over-the-counter medicine or herbal product
Ongoing or planned treatment with any of the following:\r\n* Atorvastatin\r\n* Strong inhibitors or inducers of cytochrome P family , subfamily A, polypeptide  (CYPA); as part of the enrollment/informed consent procedures, the patient will be counseled on the risk of interactions with other agents, and what to do if new medications need to be prescribed or if the patient is considering a new over-the-counter medicine or herbal product\r\n** If any of these agents have been used, patients must be off them for >=  weeks before starting study treatment
Patients who require concomitant treatment with CYPA/ strong inhibitors or inducers OTHER than antiretroviral therapies for HIV\r\n* As part of the enrollment/informed consent procedures, the patient will be counseled on the risk of interactions with other agents, and what to do if new medications need to be prescribed or if the patient is considering a new over-the-counter product\r\n* A prednisone equivalent of <  mg daily is permitted in patients requiring chronic use; larger doses must be discontinued >=  days prior to ibrutinib initiation and are prohibited during study treatment
Strong CYPA inducers and inhibitors should be avoided; selection of alternate concomitant medications with no or minimal CYPA enzyme inhibition potential is recommended; as part of the enrollment/informed consent procedures, the patient will be counseled on the risk of interactions with other agents, and what to do if new medications need to be prescribed or if the patient is considering a new over-the-counter medicine or herbal product
Patients receiving any medications or substances that are substrates of cytochrome P family , subfamily A, polypeptide  (CYPA) will be closely monitored for toxicity; as part of the enrollment/informed consent procedures, the patient will be counseled on the risk of interactions with other agents, and what to do if new medications need to be prescribed or if the patient is considering a new over-the-counter medicine or herbal product
Patients receiving any medications or substances that are strong inhibitors/inducers, sensitive substrates, or substrates with a narrow therapeutic index of cytochrome P, family , subfamily A, polypeptide  (CYPA) or permeability glycoprotein (P-gp) are ineligible; caution should be exercised when dosing dinaciclib and/or MK- concurrently with CYPA or P-gp substrates, inhibitors/inducers; if subjects are taken off a forbidden medicine, a one-week washout is required for inhibitors and two weeks for inducers; subjects on Coumadin are eligible but more frequent monitoring of the international normalized ratio (INR) (weekly during the first cycle, then at least each cycle thereafter) is recommended; as part of the enrollment/informed consent procedures, the patient will be counseled on the risk of interactions with other agents, and what to do if new medications need to be prescribed or if the patient is considering a new over-the-counter medicine or herbal product
Requires treatment with a strong cytochrome P (CYP) A inhibitor; strong inhibitors or inducers of CYPA/ should be avoided and moderate inhibitors or inducers should be used with caution; it is important to regularly consult a frequently-updated list; medical reference texts such as the Physicians Desk Reference may also provide this information; as part of the enrollment/informed consent procedures, the patient will be counseled on the risk of interactions with other agents, and what to do if new medications need to be prescribed or if the patient is considering a new over-the-counter medicine or herbal product
Patients who require concurrent treatment with any medications or substances that have significant proarrhythmic potential are ineligible
Strong CYPA inhibitors are not permitted within  days before and during the study, and strong CYPA inducers are not permitted within  days before and during the study; every effort should be made to switch patients taking such agents or substances to other medications  week prior to starting therapy, particularly patients with brain metastases who are taking enzyme-inducing anticonvulsant agents; patients who require potent CYPA inducers or inhibitors and cannot switch medications must have their case reviewed by the coordinating center PI and may be enrolled only after discussion with and agreement from the coordinating center PI; eligibility of patients receiving any medications or substances known to affect or with the potential to affect the activity or pharmacokinetics (PK) of cediranib will be determined following review of their case by the coordinating center PI
As ketoconazole may inhibit paclitaxel metabolism, patients receiving ketoconazole for any treatment indication are ineligible; patients receiving any other medications or substances that are inhibitors or inducers of cytochrome P (CYP) enzymes will be eligible; however, use all such medications or substances must be documented in the Case Report Forms
Patients receiving any medications or substances that are inhibitors or inducers of cytochrome P (CYP) enzyme(s) are ineligible
Docetaxel is a CYPA substrate and caution should be taken with its use and any drugs known to interact with it; as part of the enrollment/informed consent procedures, the patient will be counseled on the risk of interactions with other agents, and what to do if new medications need to be prescribed or if the patient is considering a new over-the-counter medicine or herbal product
Receiving any medications or substances that are inducers of CYPA
Participants receiving any medications or substances that are inhibitors or inducers of cytochrome P A are ineligible; as part of the enrollment/informed consent procedures, the patient will be counseled on the risk of interactions with other agents, and what to do if new medications need to be prescribed or if the patient is considering a new over-the-counter medicine or herbal product
Use of any drugs or substances known to be inducers of CYPA enzymes within  weeks prior to Day  or planned to be used during the overall study period.
Participants receiving any medications or substances that are inhibitors or inducers of CYPA are ineligible
Patients receiving any medications or substances that are strong inhibitors or inducers of CYPA and UGT are ineligible; the wash out period for such drugs is a minimum of  days or  half-lives whichever is shorter\r\n* Note: If a medication is incorrectly documented as prohibited in this protocol, documentation from the site pharmacist to the contrary will be acceptable for the purposes of registration